0001209191-18-018991.txt : 20180312 0001209191-18-018991.hdr.sgml : 20180312 20180312195855 ACCESSION NUMBER: 0001209191-18-018991 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180308 FILED AS OF DATE: 20180312 DATE AS OF CHANGE: 20180312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dier Mardi CENTRAL INDEX KEY: 0001574591 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35935 FILM NUMBER: 18684952 MAIL ADDRESS: STREET 1: PORTOLA PHARMACEUTICALS, INC. STREET 2: 270 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001269021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-244-6864 MAIL ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-08 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001574591 Dier Mardi C/O PORTOLA PHARMACEUTICALS, INC. 270 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Executive VP and CFO Common Stock 2018-03-08 4 D 0 10465 38.6875 D 63451 D Common Stock 2018-03-08 4 D 0 2009 39.1571 D 61442 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $39.02, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4. This number includes 31,040 unvested RSUs. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.06 to $39.28, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4. This number includes 31,040 unvested RSUs. /s/ Mike Ouimette, as attorney-in-fact 2018-03-12